Zobrazeno 1 - 10
of 121
pro vyhledávání: '"G. Vaughan Hudson"'
Publikováno v:
Clinical Oncology. 13:262-268
In order to improve treatment in early Stage IA and IIA Hodgkin's disease, the British National Lymphoma Investigation (BNLI) has evaluated two neoadjuvant chemotherapy regimens with involved field radiotherapy. This article reports the results of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145086b98287ed5750c8b49a2d2f429a
https://doi.org/10.1053/clon.2001.9265
https://doi.org/10.1053/clon.2001.9265
Autor:
B W Hancock, W M Gregory, M H Cullen, G Vaughan Hudson, A Burton, P Selby, K A Maclennan, A Jack, E M Bessell, P Smith, D C Linch, Central Lymphoma Group
Publikováno v:
British Journal of Cancer
The purpose of this randomized trial was to compare the efficacy of 6 cycles of prednisolone, Adriamycin (doxorubicin), bleomycin, vincristine (Oncovin) and etoposide (PABlOE) with 3 cycles of PABIOE that alternate with 3 cycles of chlorambucil, vinb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa40a5ffaa3794c80e878cac90366a9b
http://europepmc.org/articles/PMC2363648
http://europepmc.org/articles/PMC2363648
Publikováno v:
European Journal of Cancer. 36:384-389
The prognosis of Hodgkin's disease (HD) has improved during the last 30 years. This study was planned to analyse long-term survival of HD patients and to compare survival rates estimated from clinical trials and population-based data. Individual data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b522db8f26355e3ff9f98afba23e1795
https://doi.org/10.1016/s0959-8049(99)00267-1
https://doi.org/10.1016/s0959-8049(99)00267-1
Autor:
Walter M Gregory, J. K. Wood, Adrian C. Newland, Peter Hoskin, K. A. MacLennan, Donald Milligan, Paul Smith, David C. Linch, G. Vaughan Hudson, B. Vaughan Hudson, David Cunningham, P. A. Stevenson, Barry W. Hancock
Publikováno v:
Annals of Oncology. 11:S87-S90
Background: Between 1987 and 1991, the British National Lymphoma Investigation randomized 459 patients with non-Hodgkin's lymphoma with a large-cell component to either CHOP or the PACEBOM regimen. Patients and methods: Four hundred fifty-nine eligib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ecf1122c4eba9715e648286485c417a
https://doi.org/10.1093/annonc/11.suppl_1.s87
https://doi.org/10.1093/annonc/11.suppl_1.s87
Autor:
L Anderson, KA MacLennan, D Mason, B. Vaughan Hudson, M Burke, G. Vaughan Hudson, Peter Selby, ME Hill, David C. Linch, Paul A. Clarke, David Cunningham, F Di Stefano
Publikováno v:
Europe PubMed Central
The Bcl-2 protein is capable of preventing apoptosis, and in vitro evidence suggests a role in drug resistance. It is expressed and the gene is rearranged in a proportion of cases of large-cell non-Hodgkin's lymphoma (NHL), but the clinical significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be11c3c55bade80891fe11d1542096ed
https://doi.org/10.1182/blood.v88.3.1046.1046
https://doi.org/10.1182/blood.v88.3.1046.1046
Autor:
Patricia A. Jacobs, A. Marks, G. Vaughan Hudson, J. C. Barber, Anthony J. Swerdlow, E. J. Maher, T. Young
Publikováno v:
British Journal of Cancer
Reproductive outcomes and health of offspring were investigated in 340 patients with Hodgkin's disease first treated at Mount Vernon Hospital, Middlesex, England, at ages under 40 (females) or 45 (males) during 1970-91. Information on offspring was o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8f49a0980e37f14e6213028d53e57ff
https://doi.org/10.1038/bjc.1996.355
https://doi.org/10.1038/bjc.1996.355
Publikováno v:
British Journal of Cancer
A total of 165 adult patients with Hodgkin's disease (HD) were questioned following treatment to examine their perceptions of actual and desired involvement and provision of information in the treatment decision-making process. Irrespective of the de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6471a341fcf492f2d78c92cc73527c3e
https://doi.org/10.1038/bjc.1996.39
https://doi.org/10.1038/bjc.1996.39
Autor:
Donald Milligan, P Hoskin, David C. Linch, G. Vaughan Hudson, Barry W. Hancock, L Anderson, B. Vaughan Hudson, P. A. Stevenson, Adrian C. Newland, K. A. MacLennan, David Cunningham, J. K. Wood, Walter M Gregory
Publikováno v:
British Journal of Cancer
A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third genera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bf390bbe7b7512e658d3eb01d0dc7b
http://europepmc.org/articles/PMC2074593
http://europepmc.org/articles/PMC2074593
Publikováno v:
British Journal of Cancer
A retrospective analysis was performed of 451 adult patients with clinical stage 1/1E non-Hodgkin's lymphoma treated initially with radiotherapy alone. Histopathologically 208 patients had low-grade disease and 243 patients high-grade disease. The co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d83cf50edb8e47de909d42cbf9a74e
http://europepmc.org/articles/PMC1969460
http://europepmc.org/articles/PMC1969460
Publikováno v:
British Journal of Cancer
The risks of second primary cancer were analysed in 2846 patients with Hodgkin's disease treated within the British National Lymphoma Investigation during 1970-87. The relative risk (RR) of leukaemia was significantly greater in women (RR = 30.1; 95%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12bd4d577f5b9f20a0193e6007fa0392
https://doi.org/10.1038/bjc.1993.470
https://doi.org/10.1038/bjc.1993.470